Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS

% of readers think this story is Fact. Add your two cents.

Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR share, compared to a current price of US$2.37.

It comes after Tiziana announced, on May 25, it had begun treating a first patient with secondary progressive multiple sclerosis (SPMS) in a trial using nasally administered Foralumab – its fully-human anti-CD3 monoclonal antibody.

READ: Tiziana Life hails ‘major accomplishment as nasally administered antibody shows potential to treat degenerative diseases such as MS 

The treatment will be administered over the following six months to examine long-term safety, tolerability and clinical response, noted Zack analysts. The patient will receive 50 mcg, or 25 mcg/nostril, in three-week cycles.

Analysts at Zacks also noted they were watching teplizumab, another anti-CD3 mAb, which was indicated in Type 1 diabetes that has a target action date of July 2, 2021.

“An approval could establish a positive precedent for the drug class,” they said.

“Other foralumab trials are planned. Tiziana expects to start a progressive Multiple Sclerosis (pMS) program and will  evaluate Crohn’s Disease, both in a Phase II study in coming quarters. A Phase II study for moderate to severe COVID-19 patients is scheduled to launch this year,” the analysts added.

Sufferers of multiple sclerosis, which affects the white matter of the central nervous system,  have limited treatment options with Tysabri, sold by Biogen Inc (NASDAQ:BIIB), one of the few drugs offering relief.

The Foralumab treatment has been safely administered in a previous trial in people with COVID and was shown to be well-tolerated with no drug-related safety issues.

Tiziana Life Sciences is advancing three candidates for a variety of indications in autoimmune disease, cancer and coronavirus (COVID-19).

Zacks said its valuation assumes a 2027 regulatory approval and 2028 commercialization of foralumab for both progressive Multiple Sclerosis (pMS) and Crohn’s disease in conjunction with partners.

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Report abuse


    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    Load more ...




    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.